A randomized placebo-controlled pilot trial shows that intranasal vasopressin improves social deficits in children with autism

The social impairments of autism spectrum disorder (ASD) have a major impact on quality of life, yet there are no medications that effectively treat these core social behavior deficits. Preclinical research suggests that arginine vasopressin (AVP), a neuropeptide involved in promoting mammalian soci...

Descripció completa

Guardat en:
Dades bibliogràfiques
Publicat a:Sci Transl Med
Autors principals: Parker, Karen J., Oztan, Ozge, Libove, Robin A., Mohsin, Noreen, Karhson, Debra S., Sumiyoshi, Raena D., Summers, Jacqueline E., Hinman, Kyle E., Motonaga, Kara S., Phillips, Jennifer M., Carson, Dean S., Fung, Lawrence K., Garner, Joseph P., Hardan, Antonio Y.
Format: Artigo
Idioma:Inglês
Publicat: 2019
Matèries:
Article
Accés en línia:https://ncbi.nlm.nih.gov/pmc/articles/PMC6716148/
https://ncbi.nlm.nih.gov/pubmed/31043522
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1126/scitranslmed.aau7356
Etiquetes: Afegir etiqueta
Sense etiquetes, Sigues el primer a etiquetar aquest registre!

Ítems similars